However, these mechanisms in AML, ALL, and CLL have a wider range, which includes the prevention of ROS production, induction of autophagy, VEGF production, etc. With this in mind, treatments can be selected in a targeted way to achieve the best therapeutic response. This evidence concerns the gene VEGFA and B-cell chronic lymphocytic leukemia.